Author’s response to reviews

Title: MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4

Authors:
Lei Wang (872008532@qq.com)
Yan Chen (2722128054@qq.com)
Ya Jiang (2552624944@qq.com)
Yong Dai (doctordaiyong@163.com)
Yujun Bian (13856947818@139.com)
Kai Liu (hfsdsrmyygk@163.com)

Version: 5 Date: 15 Mar 2018

Author’s response to reviews:

BCAN-D-17-02200R4

MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4
Lei Wang; Yan Chen; Ya Jiang; Yong Dai; Yujun Bian; Kai Liu

BMC Cancer

Dear Dr., Liu,

Your manuscript "MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4" (BCAN-D-17-02200R4) has been assessed by our reviewers. Based on these reports, and my own assessment as Editor, I am pleased to inform you that it is potentially acceptable for publication in BMC Cancer, once you have carried out some essential revisions below:

1. Please note that in figure 6d, the PBS-NC/AK4 and PBS-3PM/Ki67 images appear to be duplicated. Please amend this.

A: Amended.
2. Please include a title page as the first page of your manuscript where you list the full names, institutional addresses and email addresses for all authors. The corresponding author should be indicated.

A: Added.

3. Please amend the headings of the abstract (Background; Methods; Results; Conclusions) and/or of the manuscript (Background; Methods; Results; Discussion; Conclusions) in accordance to BMC Cancer formatting.

A: Amended.

4. Please remove the ARRIVE checklist and the response to reviewers from the file inventory, as they are no longer necessary.

A: Removed.

5. As you add data as supplementary files, please also add a section "Additional files" after the references where you list the following information for each additional-supplementary file in the file inventory: - File name - Title of data - Description of data Please see http://www.biomedcentral.com/submissions/editorial-policies#availability+of+data+and+materials

A: Added.

6. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.

A: Amended.

Once you have made the necessary corrections, please submit a revised manuscript online at:

https://bcan.editorialmanager.com/
If you have forgotten your password, please use the 'Send Login Details' link on the login page at https://bcan.editorialmanager.com/. For security reasons, your password will be reset.

A point-by-point response letter must accompany your revised manuscript. This letter must provide a detailed response to each reviewer/editorial point raised, describing exactly what amendments have been made to the manuscript text and where these can be viewed (e.g. Methods section, line 12, page 5). If you disagree with any comments raised, please provide a detailed rebuttal to help explain and justify your decision.

At this stage, we ask that you submit a clean version of your manuscript and do not include track changes or highlighting.

Please also ensure that your revised manuscript conforms to the journal style, which can be found at the Submission Guidelines on the journal homepage.

Please note, if your manuscript is accepted you will not be able to make any changes to the authors, or order of authors, of your manuscript once the editor has accepted your manuscript for publication. If you wish to make any changes to authorship before you resubmit your revisions, please reply to this email and ask for a 'Request for change in authorship' form which should be completed by all authors (including those to be removed) and returned to this email address. Please ensure that any changes in authorship fulfil the criteria for authorship as outlined in BioMed Central's editorial policies (http://www.biomedcentral.com/about/editorialpolicies#authorship).

Once you have completed and returned the form, your request will be considered and you will be advised whether the requested changes will be allowed.

By resubmitting your manuscript you confirm that all author details on the revised version are correct, that all authors have agreed to authorship and order of authorship for this manuscript and that all authors have the appropriate permissions and rights to the reported data.

Please be aware that we may investigate, or ask your institute to investigate, any unauthorized attempts to change authorship or discrepancies in authorship between the submitted and revised versions of your manuscript.
A decision will be made once we have received your revised manuscript, which we expect by 23 Mar 2018.

We look forward to receiving your revised manuscript and please do not hesitate to contact us if you have any questions.

Best wishes,

Marat Gritti on behalf of

Catherine Rice

BMC Cancer

https://bmccancer.biomedcentral.com/

Technical Comments:

Editor Comments:

BMC Cancer operates a policy of open peer review, which means that you will be able to see the names of the reviewers who provided the reports via the online peer review system. We encourage you to also view the reports there, via the action links on the left-hand side of the page, to see the names of the reviewers.

Reviewer reports:

If improvements to the English language within your manuscript have been requested, you should have your manuscript reviewed by someone who is fluent in English. If you would like professional help in revising this manuscript, you can use any reputable English language editing service. We can recommend our affiliates Nature Research Editing Service (http://bit.ly/NRES_BS) and American Journal Experts (http://bit.ly/AJE_BS) for help with English usage. Please note that use of an editing service is neither a requirement nor a guarantee of publication. Free assistance is available from our English language tutorial (https://www.springer.com/gb/authors-editors/authorandreviewertutorials/writinginenglish) and our Writing resources (BMC_WRITING_RESOURCES_URL
http://www.biomedcentral.com/getpublished/writing-resources). These cover common mistakes that occur when writing in English.

----------------------
Editorial Policies
----------------------

Please read the following information and revise your manuscript as necessary. If your manuscript does not adhere to our editorial requirements this will cause a delay whilst the issue is addressed. Failure to adhere to our policies may result in rejection of your manuscript.

In accordance with BioMed Central editorial policies and formatting guidelines, all submissions to BMC Cancer must have a Declarations section which includes the mandatory sub-sections listed below. Please refer to the journal's Submission Guidelines web page for information regarding the criteria for each sub-section (https://bmccancer.biomedcentral.com/).

Where a mandatory section is not relevant to your study design or article type, for example, if your manuscript does not contain any individual persons data, please write "Not applicable" in these sections.

For the 'Availability of data and materials' section, please provide information about where the data supporting your findings can be found. We encourage authors to deposit their datasets in publicly available repositories (where available and appropriate), or to be presented within the manuscript and/or additional supporting files. Please note that identifying/confidential patient data should not be shared. Authors who do not wish to share their data must state that data will not be shared, and provide reasons for this in the manuscript text. For further guidance on how to format this section, please refer to BioMed Central's editorial policies page - http://www.biomedcentral.com/submissions/editorial-policies#availability+of+data+and+materials.

Declarations

- Ethics approval and consent to participate
- Consent to publish
- Availability of data and materials
- Competing interests
- Funding
- Authors' Contributions

- Acknowledgements

- Authors' Information